<SEC-DOCUMENT>0001051514-16-000026.txt : 20160104
<SEC-HEADER>0001051514-16-000026.hdr.sgml : 20160101
<ACCEPTANCE-DATETIME>20160104130429
ACCESSION NUMBER:		0001051514-16-000026
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160104
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160104
DATE AS OF CHANGE:		20160104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MELA SCIENCES, INC. /NY
		CENTRAL INDEX KEY:			0001051514
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				133986004
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51481
		FILM NUMBER:		161317226

	BUSINESS ADDRESS:	
		STREET 1:		100 LAKESIDE DRIVE
		STREET 2:		SUITE 100
		CITY:			HORSHAM
		STATE:			PA
		ZIP:			19044
		BUSINESS PHONE:		215-619-3200

	MAIL ADDRESS:	
		STREET 1:		100 LAKESIDE DRIVE
		STREET 2:		SUITE 100
		CITY:			HORSHAM
		STATE:			PA
		ZIP:			19044

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ELECTRO OPTICAL SCIENCES INC /NY
		DATE OF NAME CHANGE:	19971216
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form_8-k.htm
<DESCRIPTION>PRESS RELEASE DATED 1-4-16, NAME CHANGE REMINDER
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Mela Sciences
    Document created using EDGARfilings PROfile 3.6.1.0
    Copyright 1995 - 2016 Summit Financial Printing, LLC.  All rights reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div>
<hr style="BORDER-TOP: black 4px solid; HEIGHT: 10px; BORDER-BOTTOM: black 1px solid; COLOR: #ffffff; TEXT-ALIGN: center; MARGIN-LEFT: auto; BACKGROUND-COLOR: #ffffff; MARGIN-RIGHT: auto">
</div>

<div>&#160;</div>

<div>&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">UNITED STATES</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">SECURITIES AND EXCHANGE COMMISSION</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">WASHINGTON, D.C. 20549</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">_____________</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">FORM 8-K</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">CURRENT REPORT</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Pursuant to Section 13 or 15(d) of the</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Securities Exchange Act of 1934</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">Date of report (Date of earliest event reported): January 4, 2016</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center"><img style="HEIGHT: 43px; WIDTH: 122px" src="image0.jpg"></div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">MELA SCIENCES, INC.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">(Exact Name of Registrant Specified in Charter)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">&#160;</div>

<table id="8bf671ed60ef4d7f9dd19471d812c7e5" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 33.96%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Delaware</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 35.85%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">000-51481</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 30.19%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">13-3986004</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 33.96%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">(State or Other</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 35.85%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">(Commission File</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 30.19%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">(I.R.S. Employer</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 33.96%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">Jurisdiction of</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 35.85%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">Number)</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 30.19%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">Identification No.)</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 33.96%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">Incorporation)</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 35.85%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 30.19%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<table id="29e031e3223541cdb681d3841f64b13f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 9.43%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 56.26%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">100 Lakeside Drive, Suite 100, Horsham,</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Pennsylvania</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 29.59%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt">&#160;&#160;&#160;&#160;&#160;&#160; 19044</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 4.72%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 9.43%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 56.26%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">(Address of Principal Executive Offices)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 29.59%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 19.8pt">(Zip Code)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 4.72%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">Registrant's telephone number, including area code:&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">215-619-3200</font></div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">N/A</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">(Former Name or Former Address, if Changed Since Last Report)</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#61551;&#160;&#160;&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#61551;&#160;&#160;&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">&#61551;&#160;&#160;&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#61551;&#160;&#160;&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>

<div><br>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">Item 7.01.&#160;&#160;&#160;&#160;Regulation FD Disclosure.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; TEXT-INDENT: 24.2pt">On January 4, 2016, the Company issued a press release announcing its intention to change its name to Strata Skin Sciences, Inc. (the "Name Change") as disclosed in Item 8.01 of this Current Report on Form 8-K.&#160; The targeted effective date of the Name Change is January 5, 2016.&#160;&#160;A copy of the press release is furnished herewith as Exhibit 99.1.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">Item 8.01 Other Events</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">The Company has announced plans for the Name Change to Strata Skin Sciences, Inc. In connection with the Name Change, the Company also requested and reserved an updated stock trading ticker symbol, "SSKN," with respect to the Company's shares of common stock. In addition, as a result of the Name Change, the Company has been issued&#160;a new CUSIP number</font>.&#160; The Company has targeted January 5, 2016 as the effective date for these changes.</div>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">Item 9.01.&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</div>

<table id="d8c1fd1111d047b68f0061506edafae6" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 4.34%">&#160;</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 1.68%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 19%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(d)</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 74.98%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Exhibits</font></div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 4.34%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 1.68%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 19%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 74.98%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 4.34%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 1.68%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 19%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">Exhibit Number</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74.98%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">Description</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 4.34%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 1.68%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 19%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 74.98%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 4.34%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 1.68%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 19%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">99.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 74.98%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Press Release by the Company, dated January 4, 2016.</div>
</td>
</tr>
</table>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="text-align: center; font-size: 8pt; font-family: 'Times New Roman', Times, serif;">- 2 -</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: left"><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div style="MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; TEXT-INDENT: 36pt">SIGNATURE</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; TEXT-INDENT: 36pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<table id="ced01e63aca647689f9e3959d3d75fe1" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 48.12%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.11%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">MELA SCIENCES, INC.</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.77%">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 48.12%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">By:</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: black 2px solid; WIDTH: 45.11%">
<div style="TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">/s/ Michael R. Stewart&#160;&#160;&#160;&#160;&#160;</font><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.77%">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 48.12%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.11%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Michael R. Stewart&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.77%">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 48.12%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 45.11%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">President and Chief Executive Officer</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.77%">&#160;</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 12pt"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Date:&#160; January 4, 2016</div>

<div><br>
</div>

<div><br>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="text-align: center; font-size: 8pt; font-family: 'Times New Roman', Times, serif;">- 3 -</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: left"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center"><u>EXHIBIT INDEX</u></div>

<div><br>
</div>

<table id="61e6461c48e741728fceb70a7af7b9d0" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.2%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">Exhibit Number</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 78.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">Description</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 21.2%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 78.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 21.2%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">99.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 78.8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Press Release by the Company, dated January 4, 2016.</div>
</td>
</tr>
</table>

<div><br>
</div>

<div><br>
 &#160;</div>

<div>
<hr style="BORDER-TOP: black 1px solid; HEIGHT: 10px; BORDER-BOTTOM: black 4px solid; COLOR: #ffffff; TEXT-ALIGN: center; MARGIN-LEFT: auto; BACKGROUND-COLOR: #ffffff; MARGIN-RIGHT: auto">
</div>
</div>

<div id="DSPFPageNumberArea" style="text-align: center; font-size: 8pt; font-family: 'Times New Roman', Times, serif;">- 4 -</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_99-1.htm
<DESCRIPTION>PRESS RELEASE DATED JAN. 4, 2016, REMINDER OF NAME CHANGE
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Mela Sciences
    Document created using EDGARfilings PROfile 3.6.1.0
    Copyright 1995 - 2016 Summit Financial Printing, LLC.  All rights reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div>
<hr style="BORDER-TOP: black 4px solid; HEIGHT: 10px; BORDER-BOTTOM: black 1px solid; COLOR: #ffffff; TEXT-ALIGN: center; MARGIN-LEFT: auto; BACKGROUND-COLOR: #ffffff; MARGIN-RIGHT: auto">
</div>

<div>&#160;</div>

<div>&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; FONT-WEIGHT: bold; FONT-STYLE: normal; TEXT-ALIGN: right"><u>EXHIBIT 99.1</u></div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">MELA Sciences Announces That Its Corporate Name Change to STRATA Skin Sciences Will Be Effective January 5, 2016</div>

<div><br>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">HORSHAM, Pennsylvania &#8211; January 4, 2016</font> -- MELA Sciences, Inc. (Nasdaq: MELA), today announced that its corporate name change to STRATA Skin Sciences, Inc. will be effective Tuesday, January 5, 2016 and that it will trade under the symbol "SSKN" on the Nasdaq Stock Market.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">As Michael R. Stewart, President and Chief Executive Officer previously stated: "Our June 2015 XTRAC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> acquisition has expanded the dermatological opportunities that the Company is pursuing with unique, innovative technologies. Today we have over 700 dermatology accounts that include over 3,000 dermatologists, covered with a 49 person sales and marketing organization of direct sales managers, sales management, clinical specialists, reimbursement specialists and call center support personnel. During the third quarter of 2015, our first full quarter of XTRAC operations, we generated revenues of $8.3 million, including $7.0 million or 84.5% of recurring high-margin revenues, representing year over year growth of 15.9%."</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">STRATA's portfolio of products currently includes its flagship product, the XTRAC laser system for the effective treatment of psoriasis and vitiligo, as well as the VTRAC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> excimer lamp system and MelaFind, a multi-spectral digital skin lesion analysis system that assists in the identification of melanoma skin cancer.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">STRATA advocates the need for personalized medical care and best practices in medical dermatology. Commercial momentum was gained when coverage policies for XTRAC treatments were secured from virtually all insurers, including Medicare.&#160; XTRAC more recently created an expanded market outreach and awareness program aimed at the approximately 10 million psoriasis and vitiligo sufferers in the United States.&#160; To support our customers we have developed and are continually enhancing a leading call center operation of patient advocates that bridge the gap between patients looking for solutions and our network of customers<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">.</font></div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Continuing, Mr. Stewart added: "We reiterate our initial guidance of continuing revenue growth in the mid-to-high teens and further cash flow improvements going forward.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">To better reflect the broader dermatology market being served by the Company and our vision going forward, we have selected STRATA Skin Sciences as our new corporate name and are excited to officially launch this new corporate identity. The new name embodies our commitment to a wide range of therapeutic and diagnostic dermatological conditions with the common goal of increasing access, lowering costs and improving patient quality.</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">STRATA Skin Sciences enters 2016 with an infrastructure that positions us as a best-in-class player in medical dermatology and a partner-of-choice for emerging technologies looking for a strong and effective enterprise that can quickly scale and exploit unmet needs in the dermatology market<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">.</font>"</div>

<div><br>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify">About STRATA Skin Sciences (Formerly MELA Sciences, Inc.)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">STRATA Skin Sciences is a medical technology company focused on the therapeutic and diagnostic dermatology market. Its products include the XTRAC laser and VTRAC excimer lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions; and the MelaFind<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> system used to assist in the identification and management of melanoma skin cancer.</div>

<div><br>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify">Safe Harbor</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company's plans, objectives, expectations and intentions and may contain words such as "will," "may," "seeks," and "expects," that suggest future events or trends. These statements, including the Company's ability to generate the anticipated revenue stream, the Company's ability to generate sufficient cash flow to fund the Company's ongoing operations at any time in the future, and the Company's ability to build a leading franchise in medical dermatology, are based on the Company's current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company's expectations due to financial, economic, business, competitive, market, regulatory and political factors or conditions affecting the Company and the medical device industry in general, as well as more specific risks and uncertainties set forth in the Company's SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all of these forward-looking statements may prove to be incorrect or unreliable. The Company assumes no duty to update its forward-looking statements and urges investors to carefully review its SEC disclosures available at www.sec.gov and <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">www.melasciences.com</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">.</font></div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">CONTACT:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Investor Contacts:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Christina Allgeier</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">MELA Sciences, Inc.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">215-619-3267</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">callgeier@melasciences.com</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Bob Yedid</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">LifeSci Advisors, LLC</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">646-597-6989</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Bob@LifeSciAdvisors.com</div>
</div>

<div>&#160;</div>

<div>
<hr style="BORDER-TOP: black 1px solid; HEIGHT: 10px; BORDER-BOTTOM: black 4px solid; COLOR: #ffffff; TEXT-ALIGN: center; MARGIN-LEFT: auto; BACKGROUND-COLOR: #ffffff; MARGIN-RIGHT: auto">
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !D 1D# 2(  A$! Q$!_\0
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M]!/$7Q0TG1IGMK-#?W*'#;&VQJ?][O\ @*XFZ^+GB&9CY$5G;KVVQEC^9/\
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MGYG)_*O&K*&.XOH(9IEAB>0*\K=$7/)_ 5] 6OC+PE9VD-M!J]LL4*!$49X
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8$@9(KUVBBN?&I1E%+L=67R<HR;U=S__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
